Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

This study reported that while general patient characteristics and adverse event incidence for eribulin were comparable between a healthcare claims database and post-marketing surveillance, significant differences in some side effects such as neutropenia were observed.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

In this study, baricitinib treatment for severe alopecia areata was well tolerated, with minor metabolic changes and PLR emerging as a sensitive marker of treatment response.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study reported that ritlecitinib effectively improved hair regrowth in JAK inhibitor-naïve adolescent patients with severe alopecia areata, achieving significant reductions in SALT scores within 24 weeks, but was less effective for patients who had previously been treated with baricitinib.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.

In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

In this study, baricitinib was found to be effective and safe for treating severe alopecia areata, with significant hair regrowth observed in many patients by the third month of therapy and continued improvement by the twelfth month, despite mostly mild adverse events.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.